Skip to main content

Table 2 Association between main clinical variables and situation of mediastinal lymph nodes in 224 NSCLC patients

From: The value on SUV-derived parameters assessed on 18F-FDG PET/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer

Variable

Mediastinal lymph node metastasis

Total

Valuea

p value

No

Yes

SUVmax of mediastinal lymph node

   

36.378

 < 0.001

< 2.49

132 (88.0%)

18 (12.0%)

150 (67%)

  

 ≥ 2.49

38 (51.4%)

36 (48.6%)

74 (33%)

  

Primary-tumor SUVmax

   

16.525

 < 0.001

< 4.11

70 (92.1%)

6 (7.9%)

76 (33.9%)

  

 ≥ 4.11

100 (67.6%)

48 (32.4%)

148 (66.1%)

  

Primary-tumor SUVpeak

   

18.187

 < 0.001

< 2.92

73 (92.4%)

6 (7.6%)

79 (35.3%)

  

≥ 2.92

 97 (69.9%)

48 (33.1%)

145 (64.7%)

  

Primary-tumor SUVmean

   

14.430

 < 0.001

< 2.39

66 (91.7%)

6 (8.3%)

72 (32.1%)

  

 ≥ 2.39

104 (68.4%)

48 (31.6%)

152 (67.9%)

  

Primary-tumor MTV (cm3)

   

7.066

0.008

< 30.88

132 (80.5%)

32 (19.5%)

164 (73.2%)

  

 ≥ 30.88

38 (63.3%)

22 (36.7%)

60 (26.8%))

  

Primary-tumor TLG

   

10.243

0.001

< 83.53

111 (83.5%)

22 (16.5%)

133 (59.4%)

  

 ≥ 83.53

59 (64.8%)

32 (35.2%)

91 (40.6%)

  

Primary solid tumor maximum diameter (mm)

   

10.243

0.001

< 32.50

111 (83.5%)

22 (16.5%)

133 (59.4%)

  

 ≥ 32.50

59 (64.8%)

32 (35.2%)

91 (40.6%)

  

Degree of primary-tumor solidity

   

17.705

 < 0.001

Partial solid

76 (91.6%)

6 (8.4%)

83 (37.1%)

  

Solid

94 (66.7%)

47 (33.3%)

141 (62.9%)

  

CEA (ng/ml)

   

15.043

 < 0.001

 < 3.94

119 (84.4%)

22 (15.6%)

141 (62.9%)

  

 ≥ 3.94

51 (61.4%)

32 (38.6%)

83 (37.1%)

  

CYFRA21-1 (ng/ml)

   

5.16

0.023

< 2.10

48 (87.3%)

7 (12.7%)

55 (24.6%)

  

 ≥ 2.10

122 (72.2%)

47 (27.8%)

169 (75.4%)

  

CA19-9 (U/ml)

   

6.065

0.014

< 16.6

130 (80.2%)

32 (19.8%)

162 (72.3%)

  

 ≥ 16.6

40 (64.5%)

22 (35.5%)

62 (27.7%)

  

SCC (ng/ml)

   

4.199 a

0.04

 < 1.15

103 (71.5%)

41 (28.5%)

144 (64.3%)

  

 ≥ 1.15

67 (83.7%)

13 (16.3%)

80 (35.7%)

  

NSE (ng/ml)

   

4.552

0.033

 < 14.66

121 (80.1%)

30 (19.9%)

151 (67.4%)

  

 ≥ 14.66

49 (67.1%)

24 (32.9%)

73 (32.6%)

  
  1. NSCLC, non-small cell lung cancer; SUV, standardized uptake value; SUVmax, maximum SUV; SUVpeak, peak of SUV; SUVmean, average of SUV; MTV, metabolic tumor volume; TLG, total lesion glycolysis; CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin 19 fragment; CA19-9, carbohydrate antigen 19-9; SCC, squamous cell carcinoma antigen; NSE, neuron-specific enolase
  2. aPearson chi-square test
Back to article page

BMC Medical Imaging

ISSN: 1471-2342

Contact us